์ฝ˜ํ…์ธ ๋กœ ๊ฑด๋„ˆ๋›ฐ๊ธฐ
Merck

S2064

SC-560

≥98% (HPLC)

๋™์˜์–ด(๋“ค):

5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethyl pyrazole

์กฐ์ง ๋ฐ ๊ณ„์•ฝ ๊ฐ€๊ฒฉ์„ ๋ณด๋ ค๋ฉด ๋กœ๊ทธ์ธ๋ฅผ ํด๋ฆญํ•ฉ๋‹ˆ๋‹ค.

ํฌ๊ธฐ ์„ ํƒ


์ œํ’ˆ์ •๋ณด (DICE ๋ฐฐ์†ก ์‹œ ๋น„์šฉ ๋ณ„๋„)

์‹คํ—˜์‹(Hill ํ‘œ๊ธฐ๋ฒ•):
C17H12ON2ClF3
CAS ๋ฒˆํ˜ธ:
Molecular Weight:
352.74
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
Assay:
≥98% (HPLC)
Quality level:
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜

์ œํ’ˆ ์ด๋ฆ„

SC-560, ≥98% (HPLC)

InChI key

PQUGCKBLVKJMNT-UHFFFAOYSA-N

SMILES string

COc1ccc(cc1)-n2nc(cc2-c3ccc(Cl)cc3)C(F)(F)F

InChI

1S/C17H12ClF3N2O/c1-24-14-8-6-13(7-9-14)23-15(10-16(22-23)17(19,20)21)11-2-4-12(18)5-3-11/h2-10H,1H3

assay

≥98% (HPLC)

solubility

DMSO: >20 mg/mL

storage temp.

2-8ยฐC

Quality Level

Gene Information

๊ด€๋ จ ์นดํ…Œ๊ณ ๋ฆฌ

Application

SC-560 has been used as a cyclooxygenase-1 (COX-1) inhibitor to study its effects on prostaglandin E-2 (PGE2) signaling in ciliogenesis in zebrafish embryos. It has also been used as a selective inhibitor of COX-1 to study its role in PM10-induced endothelial dysfunction.

Biochem/physiol Actions

SC-560 (5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole) is a non-steroidal anti-inflammatory drug (NSAID). It is a lipophilic, diaryl heterocyclic compound. SC-560 acts as an effective antiviral agent against hepatitis C virus (HCV). It also has a potential to hinder prostaglandin E2 synthesis in neurons at nanomolar concentrations.
SC-560 belongs to the diaryl heterocycle class of cyclooxygenase (COX) inhibitors. It exhibits anti-tumor and anti-proliferative activities.
Selective cyclooxygenase-1 (COX-1) inhibitor, exhibiting 700-fold selectivity for COX-1 over COX-2.

์ €์žฅ ๋“ฑ๊ธ‰

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves


๊ฐ€์žฅ ์ตœ์‹  ๋ฒ„์ „ ์ค‘ ํ•˜๋‚˜๋ฅผ ์„ ํƒํ•˜์„ธ์š”:

์‹œํ—˜ ์„ฑ์ ์„œ(COA)

Lot/Batch Number

์ ํ•ฉํ•œ ๋ฒ„์ „์„ ์ฐพ์„ ์ˆ˜ ์—†์œผ์‹ ๊ฐ€์š”?

ํŠน์ • ๋ฒ„์ „์ด ํ•„์š”ํ•œ ๊ฒฝ์šฐ ๋กœํŠธ ๋ฒˆํ˜ธ๋‚˜ ๋ฐฐ์น˜ ๋ฒˆํ˜ธ๋กœ ํŠน์ • ์ธ์ฆ์„œ๋ฅผ ์ฐพ์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

์ด ์ œํ’ˆ์„ ์ด๋ฏธ ๊ฐ€์ง€๊ณ  ๊ณ„์‹ญ๋‹ˆ๊นŒ?

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ์—์„œ ์ตœ๊ทผ์— ๊ตฌ๋งคํ•œ ์ œํ’ˆ์— ๋Œ€ํ•œ ๋ฌธ์„œ๋ฅผ ์ฐพ์•„๋ณด์„ธ์š”.

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ ๋ฐฉ๋ฌธ

Dan Wang et al.
Antioxidants (Basel, Switzerland), 11(5) (2022-05-29)
Nuclear factor erythroid factor E2-related factor 2 (Nrf2) transcribes antioxidant genes that reduce the blood pressure (BP), yet its activation with tert-butylhydroquinone (tBHQ) in mice infused with angiotensin II (Ang II) increased mean arterial pressure (MAP) over the first 4
Edwin S L Chan et al.
Arthritis research & therapy, 9(1), R4-R4 (2007-01-25)
Both selective cyclooxygenase (COX)-2 inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs) have been beneficial pharmacological agents for many patients suffering from arthritis pain and inflammation. However, selective COX-2 inhibitors and traditional NSAIDs are both associated with heightened risk of myocardial infarction.
G O'Callaghan et al.
British journal of cancer, 99(3), 502-512 (2008-07-24)
Fas ligand (FasL/CD95L) is a member of the tumour necrosis factor superfamily that triggers apoptosis following crosslinking of the Fas receptor. Despite studies strongly implicating tumour-expressed FasL as a major inhibitor of the anti-tumour immune response, little is known about
Synthesis of Celecoxib, Mavacoxib, SC-560, Fluxapyroxad, and Bixafen Enabled by Continuous Flow Reaction Modules
Britton J, et al.
European Journal of Organic Chemistry, 2017(44), 6566-6574 (2017)
Formulation dependent pharmacokinetics, bioavailability and renal toxicity of a selective cyclooxygenase-1 inhibitor SC-560 in the rat
Teng XW, et al.
Toxicology and Applied Pharmacology, 272(1), 205-210 (2003)

๊ด€๋ จ ์ฝ˜ํ…์ธ 

Instructions

์ž์‚ฌ์˜ ๊ณผํ•™์žํŒ€์€ ์ƒ๋ช… ๊ณผํ•™, ์žฌ๋ฃŒ ๊ณผํ•™, ํ™”ํ•™ ํ•ฉ์„ฑ, ํฌ๋กœ๋งˆํ† ๊ทธ๋ž˜ํ”ผ, ๋ถ„์„ ๋ฐ ๊ธฐํƒ€ ๋งŽ์€ ์˜์—ญ์„ ํฌํ•จํ•œ ๋ชจ๋“  ๊ณผํ•™ ๋ถ„์•ผ์— ๊ฒฝํ—˜์ด ์žˆ์Šต๋‹ˆ๋‹ค..

๊ณ ๊ฐ์ง€์›ํŒ€์œผ๋กœ ์—ฐ๋ฝ๋ฐ”๋ž๋‹ˆ๋‹ค.